Association between statin medication and hearing impairment in a national health screening cohort

Kim, So Young; Lee, Chang Ho; Min, Chanyang; Yoo, Dae Myoung; Choi, Hyo Geun

doi:10.1038/s41598-021-93916-z

Cited by 6 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies on statins and sensorineural hearing loss have generally found a reduced risk of hearing impairment 27 – 29 . In a study using national health screening data, the odds ratio of hearing impairment was lower in the statin group, with a more significant effect observed in the hydrophilic statin group 9 .…”

Section: Discussionmentioning

confidence: 96%

“…Cardiovascular damage and neurodegeneration are known risk factors for hearing loss 6 – 8 . Statins, which are commonly used to treat cardiovascular and neurological disorders, may also be effective for treating hearing impairment 5 , 9 . Statins are a class of drugs that are commonly used for the treating hyperlipidemia and for preventing heart attack and stroke.…”

Section: Introductionmentioning

confidence: 99%

“…Hydrophilic statins have been found to lower serum adiponectin and C-reactive protein levels. Some previous studies have suggested the potential of hydrophilic statins to yield a more pronounced impact on the occurrence of hearing loss when contrasted with their lipophilic counterparts 9 , 10 . Other studies have investigated the association between statin intake and the risk of hearing loss and found that the association may be influenced by sex 5 , 11 , 12 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Hydrophilic and lipophilic statin use and risk of hearing loss in hyperlipidemia using a Common Data Model: multicenter cohort study

Song,

Kim,

Choi

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Hearing impairment, the third largest health burden worldwide, currently lacks definitive treatments or preventive drugs. This study compared the effects of hydrophilic and lipophilic statin on hearing loss using a common database model. This retrospective multicenter study was conducted in three hospitals in South Korea (Anam, Guro, Ansan). We enrolled patients with hyperlipidemia with an initial hearing loss diagnosis. Data were collected during January 1, 2022–December 31, 2021 using the Observational Health Data Science and Informatics open-source software and Common Data Model database. The primary outcome was the occurrence of first-time hearing loss following a hyperlipidemia diagnosis, as documented in the Common Data Model cohort database. The measures of interest were hearing loss risk between hydrophilic and lipophilic statin use. Variables were compared using propensity score matching, Cox proportional regression, and meta-analysis. Among 37,322 patients with hyperlipidemia, 13,751 (7669 men and 6082 women) and 23,631 (11,390 men and 12,241 women) were treated with hydrophilic and lipophilic statins, respectively. After propensity score matching, according to the Kaplan–Meier curve, hearing loss risk did not significantly differ among the hospitals. The hazard ratio (HR) of the male patients from Anam (0.29, [95% confidence interval (CI), 0.05–1.51]), Guro (HR, 0.56, [95% CI 0.18–1.71]), and Ansan (hazard ratio, 0.29, [95% CI 0.05–1.51]) hospitals were analyzed using Cox proportional regression. Overall effect size (HR, 0.40, [95% CI 0.18–0.91]) was estimated using meta-analysis, which indicated that hearing loss risk among hydrophilic statin users was less than that among lipophilic statin users and was statistically significant. Men in the hydrophilic statin group had a lower risk of hearing impairment than those in the lipophilic statin group.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hydrophilic and lipophilic statin use and risk of hearing loss in hyperlipidemia using a Common Data Model: multicenter cohort study

Song,

Kim,

Choi

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In humans, a recent study demonstrated that statins can reduce cisplatin ototoxicity, resulting in improved hearing thresholds after cisplatin treatment 7 . In addition, in a cohort study of a population aged ≥40 years (514,866 individuals), patients with a history of statin treatment showed a significant decrease in the prevalence of hearing impairment among the elderly compared to the non‐statin treatment group 26 . However, the therapeutic effects of statins on ISSNHL in humans have not been investigated.…”

Section: Discussionmentioning

confidence: 99%

“… 7 In addition, in a cohort study of a population aged ≥40 years (514,866 individuals), patients with a history of statin treatment showed a significant decrease in the prevalence of hearing impairment among the elderly compared to the non‐statin treatment group. 26 However, the therapeutic effects of statins on ISSNHL in humans have not been investigated. To our knowledge, this is the first study to investigate the effects of statins on hearing prognosis in patients with ISSNHL.…”

Section: Discussionmentioning

confidence: 99%

Effect of statins on hearing outcome in patients with idiopathic sudden sensorineural hearing loss

Nitta,

Kurioka,

Furuki

et al. 2023

Laryngoscope Investig Oto

View full text Add to dashboard Cite

ObjectiveStatins have been reported to improve vascular endothelial function and microcirculation, reduce oxidative stress, and exert anti‐inflammatory and protective effects against inner ear damage. Therefore, this study aimed to investigate the effect of statins on hearing prognosis in patients with idiopathic sudden sensorineural hearing loss (ISSNHL).MethodsWe reviewed the medical records of 149 patients diagnosed with ISSNHL. Clinical characteristics, hearing thresholds, statin medications, and hematological findings were investigated. First, patients with ISSNHL were assigned to the good and poor outcome groups, and factors influencing their prognosis were analyzed. Furthermore, patients with dyslipidemia were investigated to determine whether statins have therapeutic effects on ISSNHL.ResultsSignificant differences in age (p = .011), days from the onset of ISSNHL to the initiation of treatment (p = .04), and hematological total cholesterol (TC; p = .015) between the good and poor outcome groups were observed. Furthermore, when hearing outcomes were investigated in patients with dyslipidemia, TC was significantly lower in the good outcome group (p = .03). Although no significant therapeutic effects of statins were observed in participants with dyslipidemia, patients in the statin‐treated group were significantly older and experienced more diabetic complications than those in the non‐statin‐treated group.ConclusionAlthough our study showed that dyslipidemia is a poor prognostic factor for ISSNHL, statins had no significant therapeutic effects on hearing recovery in ISSNHL patients with dyslipidemia. The patients that received statin medications were significantly older and experienced more diabetic complications, which may have affected their hearing prognosis.Level of EvidenceLevel 4.

show abstract

Lipids and Statin Medication With Sensorineural Hearing Loss: A Mendelian Randomization Study

Wu,

Deng,

Luo

et al. 2024

The Laryngoscope

View full text Add to dashboard Cite

BackgroundRecent insights suggest that lipids and statin medication play a role in the development of sensorineural hearing loss (SNHL), yet the exact role remains controversial. This research applied Mendelian randomization (MR) to assess whether lipids and statin medication are associated with an increased risk of SNHL.MethodsA two‐sample MR was used in this study. Genetic instruments were constructed from variants associated with risk factors. Data for lipids and statin medication were obtained from the IEU OpenGWAS project, and for SNHL from the Finngen research project, which comprises 32,487 individuals with SNHL and 331,736 control individuals.ResultsGenetically predicted higher levels of triglycerides were associated with an increased risk of SNHL. The use of genetically predicted atorvastatin was associated with a lower risk of SNHL. Rosuvastatin has demonstrated potential in treating SNHL, yet further investigations are warranted to elucidate its relationship with SNHL. Insufficient evidence was available to suggest that the genetically predicted level of high‐density lipoprotein cholesterol or low‐density lipoprotein cholesterol or the use of simvastatin were associated with SNHL.ConclusionsThe study provides genetic evidence suggesting that increased levels of triglycerides in the blood could be a risk factor for SNHL and that the use of certain statin medications, including atorvastatin and rosuvastatin, could reduce the risk of SNHL. These results align with findings from previous observational studies that have linked hyperlipidemia with the risk of SNHL.Level of EvidenceAccording to the Oxford Centre for Evidence‐Based Medicine 2011 levels of Evidence, the study has a third level of Evidence Laryngoscope, 2024

show abstract

Association between statin medication and hearing impairment in a national health screening cohort

Cited by 6 publications

References 32 publications

Hydrophilic and lipophilic statin use and risk of hearing loss in hyperlipidemia using a Common Data Model: multicenter cohort study

Hydrophilic and lipophilic statin use and risk of hearing loss in hyperlipidemia using a Common Data Model: multicenter cohort study

Effect of statins on hearing outcome in patients with idiopathic sudden sensorineural hearing loss

Lipids and Statin Medication With Sensorineural Hearing Loss: A Mendelian Randomization Study

Contact Info

Product

Resources

About